Colleen F Reitan sold $8.4M of ALNY
director at ALNYLAM PHARMACEUTICALS, INC.. 18,000 shares at an average of $467.60, traded Sep 9, 2025, filed Sep 11, 2025.
Score components
- +15RoleDirector
- +25Trade size$8.4M at market
- +20Share of holdings soldSold 96% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000097, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 9, 2025 | MOption exercise Common Stock10b5-1 | +18,000 | $100.65 | $1.8M | 18,775 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -1,645 | $457.44 | $752k | 17,130 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -1,888 | $458.86 | $866k | 15,242 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -1,403 | $459.73 | $645k | 13,839 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -473 | $460.71 | $218k | 13,366 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -2,290 | $461.92 | $1.1M | 11,076 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -1,652 | $463.00 | $765k | 9,424 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -799 | $464.36 | $371k | 8,625 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -222 | $471.25 | $105k | 8,403 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -823 | $472.82 | $389k | 7,580 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -838 | $474.22 | $397k | 6,742 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -951 | $474.85 | $452k | 5,791 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -972 | $476.31 | $463k | 4,819 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -1,183 | $477.47 | $565k | 3,636 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -1,450 | $478.67 | $694k | 2,186 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -1,386 | $479.55 | $665k | 800 | Sep 11, 2025 |
| Sep 9, 2025 | SOpen-market sale Common Stock10b5-1 | -25 | $480.98 | $12k | 775 | Sep 11, 2025 |
| Sep 9, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -18,000 | $0.00 | $0 | 0 | Sep 11, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $5.1M 11,250 shares | -40% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $633k 1,396 shares | -6% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $3.2M 6,979 shares | -11% | |
| 62Notable | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $1.0M 2,274 shares | -4% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $633k 1,396 shares | -5% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.3M 2,851 shares | -12% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Dennis A Ausiello director | $14M 31,448 shares | -97% | |
| 35Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $16M 50,937 shares | -63% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.